Quarterly report pursuant to Section 13 or 15(d)

Licenses and Collaborations (Details Narrative)

v3.19.2
Licenses and Collaborations (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jan. 02, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Accounts receivable   $ 914   $ 914  
Revenue   592 5,670  
Merck Sharp & Dohme Corp [Member]            
Due from related parties   914   914    
Collaboration Agreement [Member]            
Proceeds from collaborators $ 4,000          
Royalty received on sales 156,000          
Accounts receivable 4,368          
Milestone upfront payment $ 4,000          
Revenue   $ 592   $ 1,302